ThursdayMay 22, 2025 3:11 pm

TinyGemsBreaks – Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) RTNova Shows Promise in Targeted Tumor Therapy

Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors. The innovative platform not only targets cancer cells effectively but also minimizes harm to surrounding healthy tissues, potentially improving treatment outcomes and reducing side effects. As global cancer rates continue to rise, Calidi’s RTNova platform and tumor-specific virotherapy hold the promise of offering new hope to cancer patients, addressing the limitations of existing treatments, and potentially improving survival rates across multiple cancer types. The company’s ongoing research and deep commitment to scientific excellence position…

Continue Reading

FridayMay 09, 2025 2:39 pm

TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Eyes Game-Changing Approach to Cancer Treatment

Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its innovative RTNova platform, which has successfully delivered transient gene-therapy payloads to targeted tumors. In addition, Calidi’s virotherapy demonstrated efficacy in killing more than 60 different tumor cell lines, showcasing the platform’s potential to revolutionize cancer treatment by enabling both tumor destruction and robust immune activation. “Targeting tumors with a systemic virotherapy with a multimodal mechanism of action, which includes direct killing of the tumors and robust activation of antitumor immune responses, may revolutionize the way we approach cancer treatments,” said a Calidi spokesman. “We are excited to have shown…

Continue Reading

ThursdayApr 17, 2025 2:40 pm

TinyGemsBreaks – SolarBank Corp.’s (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Vision in Action: Building the Grid of Tomorrow

Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., is reinforcing its role in powering the future through solar, battery storage, and EV charging projects. In recent interviews on InvestorBrandNetwork’s Bell2Bell and Electrek’s Quick Charge podcasts, CEO Richard Lu highlighted the company’s vertically integrated model, strategic partnerships—including a $50 million contract with Qcells and a new collaboration with Viridi—and its robust project pipeline exceeding 1 gigawatt of capacity. SolarBank is currently advancing…

Continue Reading

MondayApr 07, 2025 3:34 pm

TinyGemsBreaks – SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Driving Clean Energy Innovation Through Multiple Projects

Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) is a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S. The company recently announced a partnership with Viridi, the industry leader in fail-safe battery energy storage systems (“BESS”), to develop a combined 3.06 megawatt (“MW”) direct current ground-mounted solar power project and a 1.2 megawatt-hour (“MWh”) BESS, in Buffalo, New York. “This initiative aims to transform a closed landfill into a productive asset that generates clean energy for the local community. Once operational,…

Continue Reading

FridayMar 21, 2025 2:35 pm

TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI): Poised in the Future of Oncology with Cutting-Edge Treatments

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of research and development of innovative treatments in the field of immuno-oncology. With cancer being the second leading cause of death globally, the company focuses on harnessing antitumor virotherapies and patented technologies designed to protect and potentiate the virotherapy during administration to combat cancer more effectively and with fewer side effects. The company’s approach includes a systemic platform using extracellular enveloped viruses and an intratumoral platform utilizing stem cells to protect the therapy from the body’s immune system during administration. Calidi’s pipeline includes promising therapies such as RTNova,…

Continue Reading

FridayMar 14, 2025 3:41 pm

TinyGemsBreaks – Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) Novel Therapies Show Promise Against Aggressive Cancers

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company that is pioneering proprietary technology designed to attack solid tumors, empowering the immune system to combat cancer. The company was featured in a recent article that discussed its platform, which utilizes antitumor virotherapies that selectively infect and kill cancer cells while stimulating the body’s immune response. Calidi’s pipeline includes three key therapies — RTNova, SuperNova and NeuroNova — that incorporate advanced technologies such as stem cells and antitumor viruses to target and destroy cancer cells. Calidi Biotherapeutics’ innovative therapies hold the potential to revolutionize cancer treatment by enhancing efficacy and stimulating…

Continue Reading

WednesdayMar 05, 2025 2:44 pm

TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Stands at the Forefront of Integrating New Oncology Therapies

Calidi Biotherapeutics (NYSE American: CLDI) is leveraging innovative platforms in a commitment to transform cancer treatment using advanced biotechnology. “The company is pioneering therapies that combine stem cells with antitumor viruses to create powerful cancer treatments. Antitumor viruses or virotherapies selectively infect and destroy cancer cells while sparing normal cells and, when paired with stem cells, their therapeutic potential is significantly amplified,” reads a recent article. “Calidi’s pipeline includes the proprietary SuperNova (‘SNV’) platform, which utilizes allogeneic adipose-derived mesenchymal stem cells (‘AD-MSCs’) as carriers for antitumor virotherapy. This approach has shown promise in preclinical studies and safety studies, with potential applications…

Continue Reading

TuesdayDec 03, 2024 3:51 pm

TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Showcases Platform ‘Designed to Unlock New Possibilities in Cancer Therapy’

Calidi Biotherapeutics (NYSE American: CLDI) is focused on discovering more effective treatments amid projections from the American Cancer Society that 2024 will be the first year ever to see two million people diagnosed with cancer. “Calidi Biotherapeutics’ RTNova (‘CLD-400’) is an innovative systemic antitumor enveloped virotherapy designed to unlock new possibilities in cancer therapy. The platform addresses challenges presented by untargetable and untreatable metastatic diseases and offers a possible potential transformative solution with wide-ranging applications,” reads a recent article. “The company shared key information about RTNova at two recent conferences: the International Oncolytic Virotherapy Conference (‘IOVC’) in Rotterdam, Netherlands, which…

Continue Reading

FridaySep 20, 2024 3:18 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, looks to offer a better alternative to diabetes management and treatment through its patented DehydraTECH(TM) technology. “Lexaria has recently made strides with glucagon-like peptide-1 (‘GLP-1’) studies. It has reported positive interim results from an animal study on diabetes. This milestone best showcases the potential of its patented technology in not only addressing diabetes and obesity. Recently, the company announced the dosing completion of its human pilot study #2, GLP-1-H24-2, which sought to explore effective oral delivery of GLP-1 drugs. Some evaluated aspects included side effects, blood levels of…

Continue Reading

FridaySep 13, 2024 3:36 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 Program

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently released its fiscal report for the third quarter of the 2024 financial year (“Q3, 2024”). “Of note was growth in cash and marketable securities from $1.5 million during the same period in the 2023 financial year to $8.5 million as of May 31, 2024. The company reduced certain R&D expenditures and experienced other savings,” reads a recent article. “Most importantly, however, were the program updates for initiatives it embarked on for 2024. A highlight of its projects has been its glucagon-like peptide-1 (‘GLP-1’) agonist research program. GLP-1, a class of drugs, has demonstrated an…

Continue Reading

Contact us: (512) 354-7000